Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Corrections

This article was originally published in The Gray Sheet

Executive Summary

Two stories in the May 14 issue of "The Gray Sheet" misreported dates. On 1page 3, the correct date for Senate passage of the FDA Revitalization Act is May 9. On 2page 13, the HRS consensus statement on atrial fibrillation ablation was also, in fact, issued on May 9...

You may also be interested in...



HRS A-Fib Ablation Consensus Statement Offers Clinical Trial Advice

A new expert 1consensus statement on ablation of atrial fibrillation, created by a Heart Rhythm Society task force, includes 21 specific recommendations for the design and conduct of clinical trials of AF ablation devices

Senate Passes User Fee Reauthorization With FDA/Industry Proposals Intact

Legislation reauthorizing the medical device user fee program passed the Senate May 9. Action is now needed in the House to prevent the program from expiring on September 30

Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans

Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024816

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel